Valsartan-mediated chronotherapy in spontaneously hypertensive rats via targeting clock gene expression in vascular smooth muscle cells

• Published in: Archives of physiology and biochemistry 2022-03, Vol.128 (2), p.490-500
• Main Authors: Luan, Jiajie, Yang, Kui, Ding, Yanyun, Zhang, Xiaotong, Wang, Yaqin, Cui, Haiju, Zhou, Deixi, Chen, Lu, Ma, Zhangqing, Wang, Wusan, Zhang, Wen, Liu, Xiaoyun
• Format: Article
• Language: English
• Subjects: Animals; Chronotherapy; Circadian blood pressure rhythm; clock genes; Gene Expression; MLC20 phosphorylation; Muscle, Smooth, Vascular - chemistry; Muscle, Smooth, Vascular - metabolism; Rats; Rats, Inbred SHR; RNA, Messenger - genetics; Valsartan - pharmacology; valsartan chronotherapy; vascular smooth muscle cells
• ISSN: 1381-3455; 1744-4160
• DOI: 10.1080/13813455.2019.1695840

This study was to investigate the underlying mechanisms of valsartan chronotherapy in regulating blood pressure variability. RT-PCR was used to assay clock genes expression rhythm in the hypothalamus, aortic vessels, and target organs after valsartan chronotherapy. WB was used to measure Period 1 (Per1), Period 2 (Per2) protein expression in aortic vessels, as well as to measure phosphorylation of 20-kDa regulatory myosin light chain (MLC 20 ) in VSMCs. Specific clock genes in the hypothalamus, and Per1 and Per2 in aorta abdominalis, exhibited disordered circadian expression in vivo. Valsartan asleep time administration (VSA) restored circadian clock gene expression in a tissue- and gene-specific manner. In vitro, VSA was more efficient in blocking angiotensin II relative to VWA, which led to differential circadian rhythms of Per1 and Per2, ultimately corrected MLC 20 phosphorylation. VSA may be efficacious in regulating circadian clock genes rhythm, then concomitantly correct circadian blood pressure rhythms.